SYNTH-20 · Guide
Medications × training/ergogenics
Integration for the masters athlete
How this entry was checked and changed
Why this level
B only for the drug effects in the populations tested (REF-504 sedentary adults, REF-506 young healthy men); the practical column is the base's practice and transfer
Content correction 2026-09-27
Statin row: added REF-504's actual numbers (CRF +10% vs +1.5%; citrate synthase +13% vs −4.5%) and population (sedentary metabolic-syndrome adults, not athletes); CoQ10 mechanism and Kokkinos mortality claim marked as review content, not abstract-checked.
Beta-blocker row: "↓ max HR and endurance capacity (REF-506)" -> abstract gives endurance time −19.4% (bisoprolol) / −29.8% (atenolol) in 12 young healthy men and lowered resting HR; the max-HR effect labelled inference from the drug class.
Nitrate row: added n, trial count, ≥3-day dosing and the untested drug-class interaction; REF-508 marked as mechanistic review. Tier line now states the underlying trials are Tier 1.
Sync after the full-base pass: REF-504 is Tier 0 (sedentary overweight/obese, ≥2 metabolic-syndrome risk factors), not Tier 1 — Tier line and statin row updated.
"REF-508: blunting of redox-mediated adaptation by antioxidants/NSAIDs" -> REF-508 is now C+; its abstract names no drug and gives no data (drug-specific and redox content is full text); row reworded as a hypothesis and the antioxidant/NSAID advice labelled the base's own practice.
Cross-reference "[REF-009/011] anti-inflammatories and adaptation" -> REF-009 (tart cherry) did not test NSAIDs or adaptation; split and described per entry. "REF-353 nitrate ergogenic" -> time to exhaustion improves, time trials do not.
Resync 2026-09-28: Tier line "Tier 1-3 (masters and recreational athletes)" -> the underlying trials are Tier 0 (REF-504) and Tier 1 (REF-506); the earlier correction notes said this was updated, but the line still read Tier 1-3.
Resync 2026-09-28: REF-507 "no effect on 24-h BP" -> not in the REF-507 entry; replaced by what it carries (central SBP −1.56 / DBP −1.99 mmHg; effect in both healthy and hypertensive individuals).
Verification 2026-10-01: every number in the table matches its entry (REF-504: 37 adults, 40 mg/day, 12 weeks, CRF +10% vs +1.5%, citrate synthase +13% vs −4.5%; REF-506: −19.4% / −29.8%; REF-507: −2.91 / −1.45 / −1.56 / −1.99 mmHg, 47 RCTs, n=1101, ≥3 days). REF-503 abstract claims, the CoQ10 and Kokkinos caveats and the REF-508 hypothesis wording are faithful to the entries. No cited entry is flagged unverified or lacks a DOI.
Verification 2026-10-01: no fabricated clinical claim found; the problems are (a) three practical cells that give medication-adjacent instructions without a practice label or wider than the entry, (b) population — no trial in masters or trained athletes, yet the title, Tier line and Level present it as masters evidence.
Verification 2026-10-01: SYNTH-67 cites SYNTH-20 for 'prescribed nitrates'; SYNTH-20 and REF-507 contain nothing on organic nitrates. Either SYNTH-67 drops that attribution or SYNTH-20 carries it as a labelled precaution (pair 3). The correction log claims the Tier line was fixed on 2026-09-28; the live line still reads Tier 1-3.
Verification 2026-10-01: rows counted on the four table rows — none rests on evidence for the advice it gives; statin, beta-blocker and nitrate rows are evidence-for-the-effect plus unlabelled practice (mixed); the antioxidant/NSAID row is labelled practice on a hypothesis.